Table 2

Baseline characteristics
N (%) CR (n=62) TT (n=59)
Age
 Mean age at randomization (SD) 58 (11) 55 (11)
 >/=65 years old 21 (34) 13 (22)
 > 65 years old 41 (66) 46 (78)
Surgery
 Mastectomy 19 (31) 26 (31)
 Segmentectomy 43 (69) 33 (69)
 Axillary nodes 10 (16) 16 (27)
 Sentinel nodes 43 (69) 30 (51)
 Sentinel & axillary nodes 9 (15) 13 (22)
Tumor grade & nodal status
 T1 38 (61) 39 (66)
 T2 24 (39) 20 (34)
 N0 46 (74) 38 (64)
 N1, LNR 0.01-0.20 11 (69) 18 (86)
 N1, LNR 0.21-0.65 5 (31) 3 (14)
 N1, LNR >0.65 0 0
Side
 Right 30 (48) 24 (41)
 Left 32 (52) 35 (59)
Mean size of largest tumor (mm) (SD)
 T1 (<=20 mm) 12,5 (4,8) 13,4 (4,9)
 T2 (21–50 mm) 25,4 (6,9) 27,5 (5,9)
Quadrant
 Central 6 (10) 9 (15)
 Supero-interne 12 (19) 10 (17)
 Infero-interne 9 (15) 1 (2)
 Supero-externe 21 (33) 32 (54)
 Infero-externe 6 (10) 4 (7)
 Overlapping 5 (8) 2 (3)
 >/= 2 locations 3 (5) 1 (2)
Histology grade
 1 17 (27) 16 (27)
 2 25 (40) 29 (49)
 3 16 (26) 12 (20)
 Unknown 4 (7) 2 (4)
Estrogen positive 54 (87) 48 (81)
Progesterone positive 45 (73) 46 (78)
Her2 FISH positive 3 (5) 10 (17)
Adjuvant radio-chemotherapy (RT-CT) schedule
 No CT 37 (60) 29 (49)
 RT concurrent with CT 19 (30) 23 (39)
 RT after CT (sequential)* (one patient neo-adj CT) 6 (10) 7 (12)*
Chemotherapy type
 Anthracycline without taxane 4 (16) 5 (17)
 Anthracycline with taxane 16 (64) 19 (63)
 CMF 2 (8) 2 (7)
 Anthracycline with taxotere 1 (4) 3 (10)
 TCH 2 (8) 1 (3)
Hormonal therapy (HT)
 No HT 9 (14) 11 (19)
 Tamoxifen 26 (42) 16 (28)
 Femara 24 (39) 22 (38)
 Zoladex 0 2 (3)
 Tamoxifen + zoladex 3 (5) 6 (10)
 Femara + zoladex 0 1 (2)
Herceptin (Trastuzumab) 3 (5) 10 (17)

Versmessen et al.

Versmessen et al. BMC Cancer 2012 12:495   doi:10.1186/1471-2407-12-495

Open Data